Everything tagged "health care" across research, earnings, and macro.
2 articles
Abivax’s lead asset obefazimod delivered strong Phase 3 maintenance data in ulcerative colitis, shifting the story toward regulatory execution. The balance sheet is solid enough to fund the next catalysts, but the stock remains highly dependent on one program.
Align Technology remains a category leader in clear aligners with a growing digital dentistry platform and a fortress-like balance sheet. The stock looks attractive as a medium-term compounder, though pricing pressure keeps the growth story from being a pure momentum trade.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator